Literature DB >> 23902572

Orexin/hypocretin receptor signalling cascades.

J P Kukkonen1, C S Leonard.   

Abstract

Orexin (hypocretin) peptides and their two known G-protein-coupled receptors play essential roles in sleep-wake control and powerfully influence other systems regulating appetite/metabolism, stress and reward. Consequently, drugs that influence signalling by these receptors may provide novel therapeutic opportunities for treating sleep disorders, obesity and addiction. It is therefore critical to understand how these receptors operate, the nature of the signalling cascades they engage and their physiological targets. In this review, we evaluate what is currently known about orexin receptor signalling cascades, while a sister review (Leonard & Kukkonen, this issue) focuses on tissue-specific responses. The evidence suggests that orexin receptor signalling is multifaceted and is substantially more diverse than originally thought. Indeed, orexin receptors are able to couple to members of at least three G-protein families and possibly other proteins, through which they regulate non-selective cation channels, phospholipases, adenylyl cyclase, and protein and lipid kinases. In the central nervous system, orexin receptors produce neuroexcitation by postsynaptic depolarization via activation of non-selective cation channels, inhibition of K⁺ channels and activation of Na⁺/Ca²⁺ exchange, but they also can stimulate the release of neurotransmitters by presynaptic actions and modulate synaptic plasticity. Ca²⁺ signalling is also prominently influenced by these receptors, both via the classical phospholipase C-Ca²⁺ release pathway and via Ca²⁺ influx, mediated by several pathways. Upon longer-lasting stimulation, plastic effects are observed in some cell types, while others, especially cancer cells, are stimulated to die. Thus, orexin receptor signals appear highly tunable, depending on the milieu in which they are operating.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  G-protein-coupled receptor; K+ channel; Na+/K+ exchanger; adenylyl cyclase; cell death; endocannabinoid; intracellular Ca2+; non-selective cation channel; phospholipase; plasticity

Mesh:

Substances:

Year:  2014        PMID: 23902572      PMCID: PMC3904254          DOI: 10.1111/bph.12324

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  142 in total

1.  Selective enhancement of excitatory synaptic activity in the rat nucleus tractus solitarius by hypocretin 2.

Authors:  B N Smith; S F Davis; A N Van Den Pol; W Xu
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  Selective enhancement of synaptic inhibition by hypocretin (orexin) in rat vagal motor neurons: implications for autonomic regulation.

Authors:  Scott F Davis; Kevin W Williams; Weiye Xu; Nicholas R Glatzer; Bret N Smith
Journal:  J Neurosci       Date:  2003-05-01       Impact factor: 6.167

3.  Orexin-A augments voltage-gated Ca2+ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes.

Authors:  Ruwei Xu; Qinling Wang; Ming Yan; Maria Hernandez; Changhong Gong; Wah Chin Boon; Yoko Murata; Yoichi Ueta; Chen Chen
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

Review 4.  Phosphoinositide 3-kinase signalling--which way to target?

Authors:  Matthias P Wymann; Marketa Zvelebil; Muriel Laffargue
Journal:  Trends Pharmacol Sci       Date:  2003-07       Impact factor: 14.819

Review 5.  Gating of GIRK channels: details of an intricate, membrane-delimited signaling complex.

Authors:  Rona Sadja; Noga Alagem; Eitan Reuveny
Journal:  Neuron       Date:  2003-07-03       Impact factor: 17.173

6.  Effects of orexin (hypocretin) on GIRK channels.

Authors:  Q V Hoang; D Bajic; M Yanagisawa; S Nakajima; Y Nakajima
Journal:  J Neurophysiol       Date:  2003-04-17       Impact factor: 2.714

7.  Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium--calcium exchanger.

Authors:  Denis Burdakov; Birgit Liss; Frances M Ashcroft
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

8.  Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C.

Authors:  Bo Yang; Willis K Samson; Alastair V Ferguson
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

9.  Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system.

Authors:  Ying Li; Xiao Bing Gao; Takeshi Sakurai; Anthony N van den Pol
Journal:  Neuron       Date:  2002-12-19       Impact factor: 17.173

10.  Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.

Authors:  Sandrine Hilairet; Monsif Bouaboula; Dominique Carrière; Gerard Le Fur; Pierre Casellas
Journal:  J Biol Chem       Date:  2003-04-10       Impact factor: 5.157

View more
  47 in total

1.  Regulation of Lateral Hypothalamic Orexin Activity by Local GABAergic Neurons.

Authors:  Loris L Ferrari; Daniel Park; Lin Zhu; Matthew R Palmer; Rebecca Y Broadhurst; Elda Arrigoni
Journal:  J Neurosci       Date:  2018-01-08       Impact factor: 6.167

2.  Orexin A/Hypocretin Modulates Leptin Receptor-Mediated Signaling by Allosteric Modulations Mediated by the Ghrelin GHS-R1A Receptor in Hypothalamic Neurons.

Authors:  Mireia Medrano; David Aguinaga; Irene Reyes-Resina; Enric I Canela; Josefa Mallol; Gemma Navarro; Rafael Franco
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

3.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

4.  Structure-based development of a subtype-selective orexin 1 receptor antagonist.

Authors:  Jan Hellmann; Matthäus Drabek; Jie Yin; Jakub Gunera; Theresa Pröll; Frank Kraus; Christopher J Langmead; Harald Hübner; Dorothee Weikert; Peter Kolb; Daniel M Rosenbaum; Peter Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

Review 5.  Motivational activation: a unifying hypothesis of orexin/hypocretin function.

Authors:  Stephen V Mahler; David E Moorman; Rachel J Smith; Morgan H James; Gary Aston-Jones
Journal:  Nat Neurosci       Date:  2014-09-25       Impact factor: 24.884

6.  Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Authors:  Rachel I Anderson; David E Moorman; Howard C Becker
Journal:  Handb Exp Pharmacol       Date:  2018

7.  The Neuropeptide Orexin-A Inhibits the GABAA Receptor by PKC and Ca2+/CaMKII-Dependent Phosphorylation of Its β1 Subunit.

Authors:  Divya Sachidanandan; Haritha P Reddy; Anitha Mani; Geoffrey J Hyde; Amal Kanti Bera
Journal:  J Mol Neurosci       Date:  2017-01-19       Impact factor: 3.444

8.  Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus.

Authors:  Jessica R Barson; Kinning Poon; Hui Tin Ho; Mohammad I Alam; Lilia Sanzalone; Sarah F Leibowitz
Journal:  Addict Biol       Date:  2015-07-29       Impact factor: 4.280

9.  Hypocretin/Orexin Peptides Alter Spike Encoding by Serotonergic Dorsal Raphe Neurons through Two Distinct Mechanisms That Increase the Late Afterhyperpolarization.

Authors:  Masaru Ishibashi; Iryna Gumenchuk; Kenichi Miyazaki; Takafumi Inoue; William N Ross; Christopher S Leonard
Journal:  J Neurosci       Date:  2016-09-28       Impact factor: 6.167

10.  Cerebrospinal Fluid Orexin A Levels and Autonomic Function in Kleine-Levin Syndrome.

Authors:  Jing Yu Wang; Fang Han; Song X Dong; Jing Li; Pei An; Xiao Zhe Zhang; Yuan Chang; Long Zhao; Xue Li Zhang; Ya Nan Liu; Han Yan; Qing Hua Li; Yan Hu; Chang Jun Lv; Zhan Cheng Gao; Kingman P Strohl
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.